Abstract: A composition having one or more targeted opioids for administration by inhalation is provided. Targeted opioids include morphine, morphine sulfate, 6 mono acetyl morphine, morphine-6-glucuronide, morphine-6-glucuronide bromide, morphine-6-glucuronide acetate, morphine-6-glucuronide sulfate or other salt forms of these aforementioned substances. One or more targeted opioids is combined with an excipient to formulate a composition useful in the treatment of pain, anxiety or other indications. Herein, these mixtures will be referred to as “opioid compositions.” Compositions are administered in a gaseous state through the use of a novel heat-activated drug inhalation device. Kits and methods of administration of the targeted opioid composition are also provided. The composition and kit are designed for the safe delivery of opioids whereby overdose and death is extremely unlikely because of the properties of the new drug and new delivery system.
Abstract: The present disclosure describes compositions and methods to promote wound healing. The compositions and methods include an interleukin-1 beta (IL-1B) receptor antagonist (IL-1Ra), such as anakinra.
Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with steroid, NSAID, and/or adenosine triphosphatase (“ATPase”) modulator agents. In these methods, the steroidal, NSAID, and/or ATPase compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
Type:
Application
Filed:
June 2, 2017
Publication date:
April 26, 2018
Inventors:
Jay Lichter, Andrew M. Trammel, Fabrice Piu, Qiang Ye, Michael Christopher Scaife, Benedikt Vollrath, Sergio G. Duron, Luis A. Dellamary, Carl Lebel, Jeffrey P. Harris
Abstract: The present invention relates to a topical ophthalmic formulation comprising at least one antagonist of the endothelin receptor, preferably selected from sitaxentan, ambrisentan, atrasentran, bosentan, macitentan and tezosentan, or a mixture thereof, more preferably bosentan. It also relates to the use of a topical ophthalmic formulation comprising at least one antagonist of the endothelin receptor, preferably selected from sitaxentan, ambrisentan, atrasentran, bosentan, macitentan and tezosentan, or a mixture thereof, more preferably bosentan, as active ingredient for preventing and/or treating the retinal neurodegeneration induced by diabetes and/or aging.
Type:
Application
Filed:
March 22, 2016
Publication date:
April 26, 2018
Inventors:
Vicente Duran Muiños, Marta Guerrero Martínez, Cristina Hernández Pascual, José Bruno Montoro Ronsano, Rafael Simó Canonge, José María Suñé Negre, José Ramón Ticó Grau
Abstract: Provided herein is a storage stable non-fluoride toothpaste composition enriched with a dietary supplement containing both oil soluble and water soluble vitamins. The dietary supplement is incorporated into the toothpaste, the dietary supplement containing a water soluble vitamin portion including at least one water soluble vitamin and an oil soluble vitamin portion. The oil soluble vitamin portion includes at least one oil soluble vitamin, a carrier oil and an emulsifier. The toothpaste is thereby formulated in a manner such that oral application will result in systemic delivery of at least a portion of the dietary supplement to meet a 2% RDI threshold even when 3 or less serving sizes are orally applied.
Abstract: A chewing gum composition comprising cannabinoids or derivatives thereof and at least one opioid and optionally an opioid antagonist is provided. The chewing gum composition is formulated to provide controlled release of cannabinoids and opioid agonists and/or opioid antagonist during mastication. Methods to provide opioid addiction or dependence treatment, opioid addiction or dependence with concurrent cannabis addiction or dependence treatment, or pain treatment using the chewing gum composition according to this invention are also provided.
Abstract: A hydrogel composition is provided. The hydrogel composition includes polyglutamic acid (PGA) containing maleimide groups, and polyethylene glycol (PEG) containing terminal thiol groups, wherein the hydrogel composition has a pH value ranging from 4.0 to 6.5. A drug delivery system is also provided. The drug delivery system includes the above-mentioned hydrogel composition, and a pharmaceutically active ingredient encapsulated in the hydrogel composition.
Type:
Application
Filed:
October 20, 2017
Publication date:
April 26, 2018
Applicant:
Industrial Technology Research Institute
Abstract: Ultra-small Lipid Structures (USLS) with an average mean particle diameter of less than 100 nm are made using a single step process by diluting a hydro-organic solution containing lipids and passenger compounds. These particles are capable of sequestering the passenger molecules and self-assemble in a single process step into USLS. The USLS have applications in, for example, agricultural, cosmetics, pharmaceutical and food and beverage industries.
Abstract: The invention provides compositions and methods for delivering agents to localized regions, tissues, or organs in vivo by conjugating agent-loaded nanoparticles to cells having homing capability. The agents may be therapeutic or diagnostic agents such as cancer chemotherapeutic agents and imaging agents respectively.
Type:
Application
Filed:
June 16, 2017
Publication date:
April 26, 2018
Inventors:
Darrell J. IRVINE, Matthias STEPHAN, Jaehyun MOON, Anna BERSHTEYN
Abstract: Lonafarnib and ritonavir, or a pharmaceutically acceptable salt thereof, are used in combination to treat HDV infection. In one aspect, amorphous co-precipitates comprising lonafarnib, ritonavir, and a co-polymer are provided.
Abstract: Microparticles that include a charged polysaccharide (e.g., alginate) and an antimicrobial agent (e.g., chlorhexidine), along with related compositions and methods. The microparticles and related compositions can provide antimicrobial properties. Methods for manufacturing such microparticles, along with methods for applying the resulting microparticles to a substrate, such as a medical device or dressing, are also disclosed.
Type:
Application
Filed:
October 9, 2017
Publication date:
April 26, 2018
Inventors:
James Freasier, Lindsey Corum, Emir Rahislic
Abstract: A nozzle includes a nozzle body having a fluid passageway to which extension tubes are communicated. Each extension tube includes an end having an outlet port. The outlet ports are spaced from each other. An apparatus includes the nozzle, a fluid tank into which the extension tubes extends, a fluid shear device mounted in the fluid tank, and a temperature control system in which the fluid tank is mounted. A method includes filling a water phase fluid into the fluid tank. An oil phase fluid flows out of the nozzle body via the outlet ports. The water phase fluid is disturbed and flows out of the outlet ports to form semi-products of microparticles in the fluid tank. Each semi-product has an inner layer formed by the oil phase fluid and an outer layer formed by the water phase fluid. The outer layers of the semi-products are removed to form microparticles.
Abstract: Extended-release oral pharmaceutical compositions of amphetamine, a pharmaceutically acceptable salt, enantiomer, or combination thereof are provided. The compositions comprise drug-cation exchange resin complex particles which comprise extended-release coated amphetamine-cation exchange resin-matrix particles coated with an extended-release coating. Both the matrix and the extended-release coating comprise the same polymer or copolymer, and preferably the composition is devoid of uncoated amphetamine-ion exchange resin complex particles and amphetamine particles which are not complexed with an ion exchange resin.
Type:
Application
Filed:
October 20, 2017
Publication date:
April 26, 2018
Inventors:
James GAREGNANI, Paulvia Samuel Robert KENNEDY
Abstract: Disclosed is a device and method for treating a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having a film layer and a safe and effective amount of a leukotriene receptor antagonist or leukotriene synthesis inhibitor. The device is configured and formulated to achieve transmucosal and/or enteral delivery of the leukotriene receptor antagonist or leukotriene synthesis inhibitor. The method includes transmucosally and/or enterally delivering to an animal in need of treatment, a safe and effective amount of a leukotriene blocker capable of crossing the blood-brain barrier.
Type:
Application
Filed:
October 20, 2016
Publication date:
April 26, 2018
Applicant:
lntelgenx Corp.
Inventors:
Horst G. Zerbe, Rodolphe Obeid, Justin W. Conway, Nadine Paiement, Ludwig Aigner
Abstract: This document provides methods and materials for treating endometriosis. For example, methods and materials for using histone acetyl transferase inhibitors (e.g., garcinol) to treat endometriosis are provided.
Type:
Application
Filed:
January 26, 2016
Publication date:
April 26, 2018
Applicant:
Mayo Foundation for Medical Education and Research
Abstract: The present invention relates to astaxanthin compositions for use in foodstuffs, food supplements or feedstuffs or as a medicament. Astaxanthin compositions which comprise up to at least 50% by weight, in particular at least 60% by weight, particularly at least 70% by weight, specifically at least 80% by weight or at least 90% by weight, based on the total weight of astaxanthin and astaxanthin derivatives in the composition, of an astaxanthin monoester with an aliphatic, unbranched C10C22-monocarboxylic acid have a particularly good bioavailability when at least 90% by weight of the monoester present in the astaxanthin composition is a monoester with precisely one aliphatic, unbranched C10-C22-monocarboxylic acid. They are therefore particularly suitable for the use in foodstuffs, food supplements or feedstuffs and for the therapeutic use as medicament and as constituent for medicinal preparations and pharmaceutical compositions.
Abstract: Disclosed is the use of N-Methyl-D-aspartate (NMDA) antagonists at sub-anesthetic doses for the treatment of motor dysfunction in mental or psychiatric disorders with occurrence of aggressive and/or impulsive behavior.
Abstract: Provided herein are compositions and methods for treating, ameliorating, or preventing hepatocellular carcinoma in patients. In particular, the invention relates to methods of treating, ameliorating, or preventing hepatocellular carcinoma in a patient, comprising administering 6-methoxyethylamino-numonafide alone or in combination with sorafenib.
Type:
Application
Filed:
March 18, 2016
Publication date:
April 26, 2018
Applicant:
Northwestern University
Inventors:
Sui Huang, Zhi Chen, Yanning Liu, John T. Norton, Chen Wang, Guohua Lou, Richard M. Green
Abstract: This application relates to methods and compositions for the administration of disulfiram (DSF) and heavy metals zinc and copper for the treatment and prevention of medical conditions, such as cancer. DSF and copper as well as DSF and zinc form active complexes that have been shown to be effective in the treatment of cancers. However, as described herein, DSF is incompatible with either copper or zinc for simultaneous oral administration. Included herein are improved methods and oral dosage forms comprising DSF and copper and DSF and zinc in fixed dose combinations that are configured to temporally stagger release of either DSF and copper or DSF and zinc after ingestion.
Abstract: The present invention provides a composition comprising HMB and at least one probiotic. Methods of administering HMB and at least one probiotic to an animal are also described. HMB and probiotics are administered to attenuate inflammatory cytokine markers and/or maintain muscle integrity.
Abstract: The present invention is drawn to therapeutics and methods of inhibiting signaling by TLR2. The invention provides a method of treating an inflammatory disease or condition in a subject comprising administering to the subject a therapeutically effective amount of a compound of the invention or salt, solvate, hydrate, prodrug, metabolite, or combination thereof.
Abstract: Methods are disclosed to reduce apolipoprotein C-III (apoC-III) mRNA or protein in a subject in need thereof, comprising administering a pharmaceutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein R1 and R2 are independently chosen from a hydrogen atom or linear, branched, and/or cyclic C1-C6 alkyl groups, with the proviso that R1 and R2 are not both hydrogen.
Abstract: A composition which can efficiently obtain an effect of decreasing or suppressing an increase in the neutral fat level is provided. Docosahexaenoic acid (DHA) and/or eicosapentaenoic acid (EPA) is used as an active ingredient of a composition for decreasing or suppressing an increase in the neutral fat level, and the timing of intake of the active ingredient is within a time for intake within 6 hours after arousal from sleep including the breakfast time essentially including the breakfast time.
Type:
Application
Filed:
October 20, 2017
Publication date:
April 26, 2018
Applicants:
MARUHA NICHIRO CORPORATION, National Institute of Advanced Industrial Science and Technology
Abstract: A capsule oral delivery system is disclosed. The system includes an outer capsule completely enclosing an inner content, or a hard shell comprised of hydroxypropyl methylcellulose (HPMC) enclosing the content. A liquid formulation forming the inner content of the outer capsule is comprised of a hydroxycitric acid (HCA) salt, water, and glycerol, with the HCA being completely dissolved in the water and glycerol which may be the only components present in the capsule, which may be administered to a patient in a method of treatment to cause weight loss when repeatedly administered.
Abstract: The present invention relates to compounds of Formulas I-IV, which are salts of special lipid mediators of inflammation, compositions containing same, and methods of using same in the treatment of various diseases and disorders characterized by chronic or excessive inflammation, or both.
Type:
Application
Filed:
November 28, 2017
Publication date:
April 26, 2018
Inventors:
Frank C. Sciavolino, Gary Mathias, Michael C. Van Zandt, Gunnar Erik Jagdmann, JR., Jessica J. Dworak
Abstract: The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia.
Abstract: This invention relates to a suppository composition comprising cannabinoids. The suppository composition is formulated for easy absorption through mucosal membrane. The suppository as provided herein is useful for administration of cannabinoids in patients with nausea, vomiting, other conditions preventing swallowing, or conditions wherein suppository administration is required. Methods to manufacture the suppository composition are provided. Methods to treat pain, nausea, post-operative ileus and/or inflammatory bowel diseases using the suppository according to this invention are also provided.
Abstract: The disclosure includes the use of cenicriviroc or a salt or solvate thereof and pharmaceutical compositions containing the same in the treatment of inflammation and connective tissue diseases and disorders, such as fibrosis, peritonitis, and liver injury.
Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the compound. The compound is useful in therapy, for the treatment of disorders mediated by HDAC6, such as autoimmune disorders, neurodegenerative disorders and hyperproliferative disorders, such as cancer.
Type:
Application
Filed:
May 11, 2015
Publication date:
April 26, 2018
Inventors:
Johan SCHULTZ, Jan VÅGBERG, Elisabeth OLSSON, Katarina FÄRNEGÅRDH, Mattias JÖNSSON, Kristin HAMMER, Lars KRÜGER
Abstract: Therapeutically effective prodrug compounds for the prevention and treatment of cancer and pharmaceutical compositions containing these compounds as well as methods of making and using these compounds.
Type:
Application
Filed:
April 27, 2016
Publication date:
April 26, 2018
Inventors:
Tad H. KOCH, Benjamin L. BARTHEL, Hang Hubert YIN, Ryo TAMURA, Alla BALABANOVA
Abstract: Pharmaceutical compositions of (R)-pramipexole and one or more secondary therapeutic agents such as, for example, dopamine agonists, dopaminergic agonists, COMT inhibitors, MOA inhibitors, excitatory amino acid antagonists, growth factors, neurotrophic factors, antioxidants, anti-inflammatory agents, immunomodulators, anti-glutamatergics, ion channel blockers, ?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists, heat shock protein inducers/protein disaggregators and downregulators, monoamine oxidase type B (MOAB) inhibitors, multi-target agents, kinase inhibitors, Bcl inducers, histone deacetylase (HDAC) mediators, glial modulators, mitochondrial energy promoting agents, myostatin inhibitors, caspase inhibitors and combinations thereof or those related to mitochondrial dysfunction or increased oxidative stress are disclosed.
Type:
Application
Filed:
December 21, 2017
Publication date:
April 26, 2018
Inventors:
Michael E. BOZIK, Valentine GRIBKOFF, Thomas PETZINGER, JR.
Abstract: An external medicine for diffuse plexiform neurofibromas is provided. The external medicine for diffuse plexiform neurofibromas in accordance with an embodiment of the present invention contains, as an active ingredient, at least one selected from the group consisting of sirolimus and sirolimus derivatives.
Abstract: In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine, an ABCG2 inhibitor and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine and an ABCG2 inhibitor.
Type:
Application
Filed:
October 20, 2017
Publication date:
April 26, 2018
Applicant:
Glialogix, Inc.
Inventors:
Thaddeus Cromwell Reeder, Mark W. Moore, David K. Lyon, Casey K. Jager, Doug Lorenz, Corey Bloom, Kimberly Shepard
Abstract: This application relates to a method of treatment with tradipitant, and more particularly, to a method of treatment pruritus with tradipitant.
Type:
Application
Filed:
March 4, 2016
Publication date:
April 26, 2018
Inventors:
Mihael H. Polymeropoulos, Louis William Licamele
Abstract: This invention relates to the treatment of chronic kidney disease, including diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), nephrotic syndrome, non-diabetic chronic kidney disease, renal fibrosis or acute kidney injury by the administration of an RGD mimetic integrin receptor antagonist, either as a single agent or in combination with other agents.
Type:
Application
Filed:
March 24, 2016
Publication date:
April 26, 2018
Applicant:
Merck Sharp & Dohme Corp
Inventors:
Jason M. COX, Lijun MA, Xiaoyan ZHOU, Robin E. HAIMBACH, Paul J. COLEMAN, Haihong ZHOU, David E. KELLEY, Selwyn Aubrey STOCH, Le T. DUONG, Maarten HOEK
Abstract: This invention relates to pharmaceutical formulations comprising 1-(2-thien-2?-yl-2-oxo-ethyl)-3-(methanesulfonyl hydrazine carbonyl) pyridinium, its pharmaceutically acceptable salts, salt-cocrystals and co-crystals, particularly 1-(2-thien-2?-yl-2-oxo-ethyl)-3-5(methanesulfonyl hydrazine carbonyl) pyridinium chloride. The formulations are suitable for oral administration and also comprise a permeability enhancer or a suitable base or a mixture thereof.
Abstract: The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.
Type:
Application
Filed:
December 8, 2017
Publication date:
April 26, 2018
Inventors:
Curt D. Wolfgang, Mihael H. Polymeropoulos
Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
Type:
Application
Filed:
December 19, 2017
Publication date:
April 26, 2018
Inventors:
Dalton King, Lorin A. Thompson, III, Jianliang Shi, Srinivasan Thangathirupathy, Jayakumar Sankara Warrier, Imadul Islam, John E. Macor
Abstract: This application relates to methods of treating attention deficit hyperactivity disorder (ADHD), 22q deletion and/or duplication syndrome, and co-morbidities with a nonselective activator of metabotropic glutamate receptors, such as fasoracetam, for example, in subjects having a genetic alteration in at least one metabotropic glutamate receptor (mGluR) network gene.
Type:
Application
Filed:
December 21, 2017
Publication date:
April 26, 2018
Applicant:
The Children's Hospital of Philadelphia
Abstract: The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment.
Type:
Application
Filed:
June 1, 2017
Publication date:
April 26, 2018
Inventors:
Maryka QUIK, Donato DI MONTE, J. William LANGSTON
Abstract: The present invention relates to crystalline forms of cabozantinib succinate (Form A) and cabozantinib acetate (Form A-1) and to pharmaceutical compositions comprising said crystalline forms and their use as anti-cancer medicaments.
Type:
Application
Filed:
March 22, 2016
Publication date:
April 26, 2018
Applicant:
Sandoz AG
Inventors:
Marijan STEFINOVIC, Erwin Paul SCHREINER
Abstract: The present invention is directed to ferroptosis and glutaminolysis inhibitors and to methods of treatment or prevention of an organ injury caused by ischemia-reperfusion in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a ferroptosis inhibitor or a glutaminolysis inhibitor.
Abstract: Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.
Type:
Application
Filed:
July 10, 2017
Publication date:
April 26, 2018
Inventors:
Daryl C. Drummond, Dmitri B. Kirpotin, Mark Eamon Hayes, Charles Noble, Kevin Kesper, Antoine M. Awad, Douglas J. Moore, Andrew J. O'Brien
Abstract: The present invention relates to therapeutic ADCs comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment. The ADC may be administered at a dosage of between 4 mg/kg and 18 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg, most preferably 8 to 10 mg/kg. When administered at specified dosages and schedules, the ADC can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Preferably, the ADC is administered in combination with one or more other therapeutic agents, such as a PARP inhibitor, a microtubule inhibitor, a Bruton kinase inhibitor or a PI3K inhibitor. Most preferably, the ADC is of use for treating a Trop-2 expressing cancer, such as metastatic urothelial cancer.
Type:
Application
Filed:
November 22, 2017
Publication date:
April 26, 2018
Inventors:
Serengulam V. Govindan, David M. Goldenberg
Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
Type:
Application
Filed:
October 26, 2017
Publication date:
April 26, 2018
Inventors:
Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
Abstract: Methods and composition for treating or preventing pulmonary hypertension are provided. In certain aspects, compounds that inhibit TH17 cell maturation or activity, such as retinoic acid receptor-related orphan nuclear receptor (ROR) inhibitors, are used to for the treatment of pulmonary hypertension.
Type:
Application
Filed:
April 28, 2016
Publication date:
April 26, 2018
Applicant:
STC. UNM
Inventors:
Laura V. Gonzalez Bosc, Levi D. Maston, Thomas Resta